Hemab
Seedtable Score
52
Startups
3
Funding Rounds
2
Investors
$190m
Money raised
Overview
Hemab, based in Copenhagen, shows strong potential with its focus on innovative treatments for genetic bleeding disorders. Their work addresses critical gaps in the market, where existing treatments often require frequent transfusions and result in high medical costs and reduced quality of life for patients. By developing more effective therapies, Hemab aims to improve patient outcomes and capture a substantial market share. Supported by investors like Novo A/S and HealthCap, Hemab is well-positioned to advance its research and introduce transformative therapies to a market in need of innovation.
- Website: https://hemab.com
- Business model: b2b
- Company size: 1 - 11 employees
- Headquarters: Copenhagen, Denmark
- Founded: 2017
- Social accounts: Linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Funding
Funding series
Funding Series Analysis
The company Hemab has raised a total of $190m in funding over 3 rounds.
Key Insights:
- Series A: $55m
- Unknown: $
- Series B: $135m
Hemab Unknown (2020, $0M)
$
Hemab Series A (2021, $55M)
$55m
Hemab Series B (2023, $135M)
$135m